Trials / Enrolling By Invitation
Enrolling By InvitationNCT07007637
A Study to Evaluate the Long-term Safety, Tolerability, and Efficacy of Subcutaneous Sonelokimab in Participants With Moderate to Severe Hidradenitis Suppurativa
A Phase 3, Multicenter, Open-label Extension Study to Evaluate the Long-term Safety, Tolerability, and Efficacy of Subcutaneous Sonelokimab in Participants With Moderate to Severe Hidradenitis Suppurativa
- Status
- Enrolling By Invitation
- Phase
- Phase 3
- Study type
- Interventional
- Enrollment
- 835 (estimated)
- Sponsor
- MoonLake Immunotherapeutics AG · Industry
- Sex
- All
- Age
- 12 Years
- Healthy volunteers
- Not accepted
Summary
This is a study to evaluate the long-term safety, tolerability, and efficacy of sonelokimab in participants with moderate to severe hidradenitis suppurativa who were previously enrolled in a parental study.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Sonelokimab | Sonelokimab |
Timeline
- Start date
- 2025-06-27
- Primary completion
- 2028-06-13
- Completion
- 2028-06-13
- First posted
- 2025-06-06
- Last updated
- 2026-03-09
Locations
88 sites across 11 countries: United States, Belgium, Bulgaria, Canada, France, Germany, Hungary, Italy, Norway, Poland, Spain
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT07007637. Inclusion in this directory is not an endorsement.